Faust Pharmaceuticals Announces Research Agreement with Takeda
News Jan 08, 2008
Faust Pharmaceuticals S.A. has announced that it has entered into a research agreement with Takeda Pharmaceutical Company Limited. Under the agreement, Faust will apply its NEUROCLID™ platform to identify drug candidates that target undisclosed G Protein-Coupled Receptors (GPCRs) of interest to Takeda.
"We are delighted to commence this research agreement with Takeda," noted Thomas Seoh, CEO of Faust. "The interactions between the Takeda and Faust research teams in planning these projects have been extremely high quality, and we very much look forward to applying our NEUROCLID™ GPCR platform to try to identify novel compounds and compound families for these promising GPCR targets."
"Faust's innovative NEUROCLID™ GPCR platform is a unique approach for discovering new chemical series for targeting challenging GPCRs," commented Dr. Shigenori Ohkawa, General Manager of the Takeda Pharmaceutical Research Division.
"Faust's NEUROCLID™ platform is a promising example of state-of-the-art technologies that Takeda is willing to access from around the world in our search for novel drugs against these important drug targets."
Financial terms of the research agreement were not disclosed.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE